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Introduction {#hep41113-sec-0001}
============

Chronic hepatitis B virus (HBV) is a global disease. The majority of carriers of hepatitis B surface antigen (HBsAg) are inhabitants of Africa and Asia.[1](#hep41113-bib-0001){ref-type="ref"}, [2](#hep41113-bib-0002){ref-type="ref"} Immune tolerance is a hallmark of persistent HBV infection.[3](#hep41113-bib-0003){ref-type="ref"} Typically, patients with chronic hepatitis B are infected through their parents in the early stage of life.[4](#hep41113-bib-0004){ref-type="ref"} Remarkably, the immune system of the host may respond to the HBV[5](#hep41113-bib-0005){ref-type="ref"} but does not produce the immune clearance of HBV. HBV may replicate in host cells peacefully until they enter immune clearance phases 2‐4 decades later.[3](#hep41113-bib-0003){ref-type="ref"} If the HBV can be eradicated, HBV replication will be terminated, and ultimately 50% of hosts may clear HBsAg by 80 years of age.[6](#hep41113-bib-0006){ref-type="ref"} Genome‐wide association studies from Asia have revealed that the human leukocyte antigen (HLA)‐DP and HLA‐DQ loci play roles in persistent HBV infection. [7](#hep41113-bib-0007){ref-type="ref"}, [8](#hep41113-bib-0008){ref-type="ref"}, [9](#hep41113-bib-0009){ref-type="ref"}, [10](#hep41113-bib-0010){ref-type="ref"}, [11](#hep41113-bib-0011){ref-type="ref"}, [12](#hep41113-bib-0012){ref-type="ref"}, [13](#hep41113-bib-0013){ref-type="ref"} Our objective is to understand the evolution of the single nucleotide polymorphisms (SNPs) that were responsible for HBV‐related immune tolerance during human migration and to correlate the HBV‐related SNPs with a prevalence of chronic HBV infection among global populations. Based on the data from 1,000 genomes collected worldwide, we conducted a global perspective study on the allele frequency of hepatitis‐related SNPs.

Materials and Methods {#hep41113-sec-0002}
=====================

Based on a literature review, 12 HBV‐ and HLA‐related SNPs,[7](#hep41113-bib-0007){ref-type="ref"}, [8](#hep41113-bib-0008){ref-type="ref"}, [9](#hep41113-bib-0009){ref-type="ref"}, [10](#hep41113-bib-0010){ref-type="ref"}, [11](#hep41113-bib-0011){ref-type="ref"}, [12](#hep41113-bib-0012){ref-type="ref"}, [13](#hep41113-bib-0013){ref-type="ref"} five hepatitis‐ and immune‐related SNPs in complement factor B (CFB), clusters of differentiation molecule 40 (CD40), and interferon lambda 4 (IFNL4) loci[14](#hep41113-bib-0014){ref-type="ref"}, [15](#hep41113-bib-0015){ref-type="ref"}, [16](#hep41113-bib-0016){ref-type="ref"}, [17](#hep41113-bib-0017){ref-type="ref"}, [18](#hep41113-bib-0018){ref-type="ref"}, and five nasopharyngeal carcinoma (NPC)‐related SNPs in HLA regions[19](#hep41113-bib-0019){ref-type="ref"}, [20](#hep41113-bib-0020){ref-type="ref"}, [21](#hep41113-bib-0021){ref-type="ref"} were selected for this analysis (Tables [1](#hep41113-tbl-0001){ref-type="table-wrap"} and [2](#hep41113-tbl-0002){ref-type="table-wrap"}). These SNP data from around the world were downloaded from the phase 3 data of 1,000 genomes (<http://www.1000genomes.org/>).[22](#hep41113-bib-0022){ref-type="ref"} The subjects participating in the 1,000 genome project were older than 18 years and had three out of four grandparents who identified themselves as members of the group. The location of the 26 populations evaluated in the 1,000 genomes are shown by abbreviation on a global HBsAg prevalence map reported by Hou et al.[2](#hep41113-bib-0002){ref-type="ref"} (Fig. [1](#hep41113-fig-0001){ref-type="fig"}). The allele frequencies of different geographic groups in viral hepatitis‐related SNPs and NPC‐related SNPs are illustrated in Fig. [2](#hep41113-fig-0002){ref-type="fig"}. The SNP genotype differences between groups are listed in Tables [1](#hep41113-tbl-0001){ref-type="table-wrap"} and [2](#hep41113-tbl-0002){ref-type="table-wrap"}. We used interactive chi‐square tests to calculate the difference in genotypes between groups ([http://quantpsy.org](http://quantpsy.org/)).

###### 

GENOTYPE DIFFERENCES BETWEEN GEOGRAPHIC AREAS ON HEPATITIS‐ AND IMMUNE‐RELATED SNPs

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                     TSI\        ESN\       TSI Vs.\   LWK (n = 103)   GIH\         LWK Vs. GIH   BEB\       CDX\       BEB Vs.\                                          
                     (n = 107)   (n = 99)   ESN                        (n = 99)                   (n = 86)   (n = 93)   CDX                                               
  ------------- ---- ----------- ---------- ---------- --------------- ------------ ------------- ---------- ---------- ---------- ------------- ---- ------ ----- ------ ------------
  rs12614       CC   76          71.0       37         37.4                         45            45.5       74         71.9                     68   79.1   90    96.8   

  CFB           CT   29          27.1       47         47.5                         45            45.5       25         24.3                     17   19.8   3     3.2    

                TT   2           1.9        15         15.1            1.1×10^−6^   9             9.0        4          3.9        6.25×10^−6^   1    1.2    0     0      1.1×10^−3^

  rs12979860    CC   37          34.6       8          8.1                          18            18.2       62         60.2                     53   61.6   75    80.6   

  IFNL4         CT   55          51.4       41         41.4                         60            60.6       33         32.0                     32   37.2   17    18.3   

                TT   15          14.0       50         50.5            0.0000       21            21.2       8          7.8        6.6×10^−4^    1    1.2    1     1.1    1.7×10^−2^

  rs368234815   ‐‐   15          14.0       52         52.5                         25            25.3       8          7.8                      1    1.2    1     1.1    

  IFNL4         ‐T   56          52.3       38         38.4                         60            60.6       33         32.0                     33   38.4   17    18.3   

                TT   36          33.7       9          9.1             0.0000       14            14.1       62         60.2       0.0000        52   60.5   75    80.6   1.1×10^−2^

  rs8099917     TT   64          59.8       95         96.0                         84            84.8       72         69.9                     67   77.9   75    80.6   

  IFNL4\        GT   42          39.3       4          4.0                          15            15.2       29         28.2                     19   22.1   18    19.4   
  MSRB1P1                                                                                                                                                                 

                GG   1           0.9        0          0               1×10^−8^     0             0          2          1.9        2.6×10^−2^    0    0      0.0   0.0    1.0000

  rs1883832     TT   2           1.9        0          0                            0             0          6          5.8                      9    10.5   29    31.2   

  CD40          CT   60          56.1       0          0                            8             8.1        46         44.7                     36   41.9   44    47.3   

                CC   45          42.1       99         100             0.0000       91            91.9       51         49.5       0.0000        41   47.7   20    21.5   1.7×10^−2^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BEB, Bengali populations from Bangladesh; CDX, Chinese Dai populations in Xishuangbanna, China; ESN, Esan in Nigeria; GIH, Gujarati in India from Houston, TX; LWK, Luhya in Webuye, Kenya; MSRB1P1, methionine sulfoxide reductase B1 pseudogene 1; TSI, Toscani in Italy.

###### 

GENOTYPE DIFFERENCES BETWEEN GEOGRAPHIC AREAS ON HBV‐ AND HLA‐RELATED SNPs

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                     TSI\        ESN\       TSI Vs.\   LWK (n = 103)   GIH\         LWK Vs. GIH   BEB\       CDX\       BEB Vs.\                                        
                     (n = 107)   (n = 99)   ESN                        (n = 99)                   (n = 86)   (n = 93)   CDX                                             
  ------------- ---- ----------- ---------- ---------- --------------- ------------ ------------- ---------- ---------- ---------- ------------ ---- ------ ---- ------ ------------
  rs9276370     GG   16          15.0       53         53.5                         41            41.4       6          5.8                     0    0.0    0    0.0    

  HLA‐DQA2      GT   42          39.3       41         41.4                         43            43.4       34         33.0                    22   25.6   18   19.4   

                TT   49          45.8       5          5.1             0.0000       15            15.2       63         61.2       0.0000       64   74.4   75   80.6   0.6071

  rs7756516     CC   13          12.1       41         41.4                         29            29.3       13         12.6                    2    2.3    0    0.0    

  HLA‐DQB2      CT   54          50.5       49         49.5                         47            47.5       47         45.6                    35   40.7   20   21.5   

                TT   40          37.4       9          9.1             4.0×10^−8^   23            23.2       43         41.7       2.3×10^−3^   49   57.0   73   78.5   5.1×10^−3^

  rs7453920     AA   12          11.2       8          8.1                          7             7.1        6          5.8                     0    0.0    0    0.0    

  HLA‐DQB2      AG   41          38.3       48         48.5                         42            42.4       29         28.2                    19   22.1   11   11.8   

                GG   54          50.5       43         43.4            0.3181       50            50.5       68         66.0       0.0771       67   77.9   82   88.2   0.1850

  rs9277341     TT   44          41.1       6          6.1                          18            18.2       21         20.4                    14   16.3   1    1.1    

  HLA‐DPA1      CT   47          43.9       41         41.4                         43            43.4       57         55.3                    42   48.8   23   24.7   

                CC   16          15.0       52         52.5            0.0000       38            38.4       25         24.3       0.0909       30   34.9   69   74.2   1.1×10^−7^

  rs3135021     GG   55          51.4       45         45.5                         33            33.3       26         25.2                    29   33.7   65   69.9   

  HLA‐DPA1/B1   AG   40          37.4       43         43.4                         46            46.5       63         61.2                    45   52.3   27   29.0   

                AA   12          11.2       11         11.1            0.6561       20            20.2       14         13.6       0.1074       12   14.0   1    1.1    1.1×10^−6^

  rs9277535     AA   51          47.7       61         61.6                         62            62.6       52         50.5                    40   46.5   13   14.0   

  HLA‐DPB1      AG   50          46.7       34         34.3                         32            32.3       48         46.6                    30   34.9   42   45.2   

                GG   6           5.6        4          4.0             0.1329       5             5.1        3          2.9        0.0949       16   18.6   38   40.9   4.8×10^−6^

  rs10484569    GG   100         93.5       83         83.8                         88            88.9       95         92.2                    82   95.3   33   35.5   

  HLA‐DPA2      AG   7           6.5        15         15.2                         10            10.1       8          7.8                     3    3.5    41   44.1   

                AA   0           0.0        1          1.0             0.0748       1             1.0        0          0.0        0.4939       1    1.2    19   20.4   0.0000

  rs3128917     TT   54          50.5       25         25.3                         28            28.3       59         57.3                    44   51.2   22   23.7   

  HLA‐DPA2      GT   44          41.1       48         48.5                         51            51.5       39         37.9                    32   37.2   42   45.2   

                GG   9           8.4        26         26.3            8.3×10^−5^   20            20.2       5          4.9        2.1×10^−5^   10   11.6   29   31.2   1.4×10^−4^

  rs2281388     GG   103         96.3       99         100.0                        99            100        96         93.2                    81   94.2   33   35.5   

  HLA‐DPA2      AG   4           3.7        0          0.0                          0             0.0        7          6.8                     4    4.7    41   44.1   

                GG   0           0.0        0          0.0             0.1516       0             0.0        0          0.0        0.0307       1    1.2    19   20.4   0.0000

  rs3117222     CC   54          50.5       25         25.3                         28            28.3       59         57.3                    44   51.2   21   22.6   

  HLA‐DPA2      CT   44          41.1       50         50.5                         51            51.5       39         37.9                    32   37.2   43   46.2   

                TT   9           8.4        24         24.2            1.5×10^−4^   20            20.2       5          4.9        2.1×10^−5^   10   11.6   29   31.2   8.4×10^−5^

  rs9380343     CC   99          92.5       93         93.9                         95            96.0       95         92.2                    82   95.3   31   33.3   

  HLA‐DPB2      CT   8           7.5        6          6.1                          4             4.0        8          7.8                     3    3.5    43   46.2   

                TT   0           0.0        0          0.0             0.9217       0             0.0        0          0.0        0.5339       1    1.2    19   20.4   0.0000

  rs9366816     TT   65          60.7       65         65.7                         64            64.6       65         63.1                    58   67.4   24   25.8   

  HLA‐DPA3      CT   37          34.6       29         29.3                         32            32.3       35         34.0                    25   29.1   47   50.5   

                CC   5           4.7        5          5.1             0.7189       3             3.0        3          2.9        0.9690       3    3.5    22   23.7   2.0×10^−8^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BEB, Bengali populations from Bangladesh; CDX, Chinese Dai populations in Xishuangbanna, China; ESN, Esan in Nigeria; GIH, Gujarati in India from Houston, TX; LWK, Luhya in Webuye, Kenya; MSRB1P1, methionine sulfoxide reductase B1 pseudogene 1; TSI, Toscani in Italy.

![Global HBsAg prevalence before HBV vaccination and the locations of the population groups of 1,000 genomes. The boxed groups are populations used in Tables [1](#hep41113-tbl-0001){ref-type="table-wrap"} and [2](#hep41113-tbl-0002){ref-type="table-wrap"}. (Modified from Hou et al., Int J Med Sci 2005; 2:50‐57.) Abbreviations: ACB, African Ancestry from Barbados in the Caribbean; ASW, African ancestry in Southwest United States; BEB, Bengali in Bangladesh; CDX, Chinese Dai in Xishuangbanna, China; CEU, Utah residents with ancestry from Northern and Western Europe; CHB, Han Chinese in Beijing, China; CHS, Han Chinese South, China; CLM, Colombians in Medellin, Colombia; ESN, Esan from Nigeria; FIN, Finnish in Finland; GBR, British from England and Scotland, United Kingdom; GDW, Gambian in Western division, Gambia, GIH, Gujarati Indians in Houston, TX; IBS, Iberian populations in Spain; ITU, Indian Telugu in the United Kingdom; JPT, Japanese in Tokyo, Japan; KHV, Kinh in Hochi Minh city, Vietnam; LWK, Luhya in Webuye, Kenya; MSL, Mende in Sierra Leone; MXL, Mexican ancestry in Los Angeles, CA; PEL, Peruvian in Lima, Peru; PJL, Punjabi in Lahore, Pakistan; PUR, Puerto Ricans in Puerto Rico; STU, Sri Lankan Tamil in the United Kingdom; TSI, Toscani in Italy; YRI, Yoruba in Ibadan, Nigeria.](HEP4-1-1005-g001){#hep41113-fig-0001}

![Allele frequency of viral hepatitis‐ and NPC‐related SNPs in different geographic groups. (A) Allele frequency of immune‐related SNPs (CFB, CD40, IFNL4). Significant allele type differences were found between African and European populations and between African and South Asian populations in all of the immune‐related SNPs. (B) Allele frequency of HBV‐ and HLA‐related SNPs (HLA‐DP and ‐DQ). Significant allele type differences were found between South and East Asian populations in 8 of 12 HLA‐related SNPs and between African and South Asian populations in 3 of 12 SNPs. (C) Allele frequency of NPC‐related SNPs (HLA regions). There was no significant difference among different populations in five NPC‐related SNPs. Abbreviations: ACB, African Ancestry from Barbados in the Caribbean; AFR, Africa, total; ALL, global, total; AMR, America, total; ASW, African ancestry in Southwest United States; BEB, Bengali in Bangladesh; CDX, Chinese Dai in Xishuangbanna, China; CEU, Utah residents with ancestry from Northern and Western Europe; CHB, Han Chinese in Beijing, China; CHS, Han Chinese South, China; CLM, Colombians in Medellin, Colombia; EAS, East Asia, total; ESN, Esan from Nigeria; EUR, Europe, total; FIN, Finnish in Finland; GBR, British from England and Scotland, United Kingdom; GIH, Gujarati Indians in Houston, TX; IBS, Iberian populations in Spain; ITU, Indian Telugu in the United Kingdom; JPT, Japanese in Tokyo, Japan; KHV, Kinh in Hochi Minh city, Vietnam; LWK, Luhya in Webuye, Kenya; MAG, Mandinka in Gambia; MSL, Mende in Sierra Leone; MXL, Mexican ancestry in Los Angeles, CA; PEL, Peruvian in Lima, Peru; PJL, Punjabi in Lahore, Pakistan; PUR, Puerto Ricans in Puerto Rico; SAS, South Asia, total; STU, Sri Lankan Tamil in the United Kingdom; TSI, Toscani in Italy; YRI, Yoruba in Ibadan, Nigeria.](HEP4-1-1005-g002){#hep41113-fig-0002}

Results {#hep41113-sec-0003}
=======

Among two HBV‐ and immune‐related SNPs in the CFB and CD40 regions[14](#hep41113-bib-0014){ref-type="ref"}, [15](#hep41113-bib-0015){ref-type="ref"} and three hepatitis C virus‐related SNPs in the IFNL4 regions,[16](#hep41113-bib-0016){ref-type="ref"}, [17](#hep41113-bib-0017){ref-type="ref"}, [18](#hep41113-bib-0018){ref-type="ref"} allele type differences can be found between Africa and Europe or between Africa and South Asia (Fig. [2](#hep41113-fig-0002){ref-type="fig"}A). All these immune‐related SNP genotypes differed significantly between Esan in Nigeria and Toscani in Italy and between Luhya in Webuye, Kenya (LWK) and Gujarati in India (GIH) (Table [1](#hep41113-tbl-0001){ref-type="table-wrap"}; *P \<* 0.001).

Among 12 HBV‐ and HLA‐related SNPs,[7](#hep41113-bib-0007){ref-type="ref"}, [8](#hep41113-bib-0008){ref-type="ref"}, [9](#hep41113-bib-0009){ref-type="ref"}, [10](#hep41113-bib-0010){ref-type="ref"}, [11](#hep41113-bib-0011){ref-type="ref"}, [12](#hep41113-bib-0012){ref-type="ref"}, [13](#hep41113-bib-0013){ref-type="ref"} the allele frequency showed marked differences between South and East Asian genome samples (Fig. [2](#hep41113-fig-0002){ref-type="fig"}B). Eight of the 12 SNPs differed significantly between Bengali in Bangladesh (BEB) and Chinese Dai in Xishuangbanna, China (CDX); these areas represent the junction of South and East Asia (Table [2](#hep41113-tbl-0002){ref-type="table-wrap"}; *P \<* 0.001).

Three of the 12 HBV‐ and HLA‐related SNPs (Fig. [2](#hep41113-fig-0002){ref-type="fig"}B, dotted lines; rs9276370, rs3128917, and rs9380343) also showed significant differences between LWK in Africa and GIH in South Asia (Table [2](#hep41113-tbl-0002){ref-type="table-wrap"}; *P \<* 0.001). In contrast, we found the allele frequency of NPC‐related SNPs[18](#hep41113-bib-0018){ref-type="ref"}, [19](#hep41113-bib-0019){ref-type="ref"}, [20](#hep41113-bib-0020){ref-type="ref"} to be relatively stable among different populations (Fig. [2](#hep41113-fig-0002){ref-type="fig"}C).

Discussion {#hep41113-sec-0004}
==========

Based on the well‐known human migration pathways[23](#hep41113-bib-0023){ref-type="ref"}, [24](#hep41113-bib-0024){ref-type="ref"} and the recent data from 1,000 genomes,[22](#hep41113-bib-0022){ref-type="ref"} our analysis of hepatitis‐ and immune‐related SNPs demonstrate a significant change in allele frequency shortly after the migration out of Africa (Fig. [2](#hep41113-fig-0002){ref-type="fig"}A). All genotypes of five immune‐related SNPs differed significantly between Esan in Nigeria in Africa and Toscani in Italy in Europe and between LWK in Africa and GIH in South Asia (Table [1](#hep41113-tbl-0001){ref-type="table-wrap"}; *P \<* 0.001). In addition, both CFB and CD40 shifted from a higher expression in African genotypes (rs12614:TT; rs1883832:CC) to a lower expression in European and South Asian genotypes (rs12614:CC; rs1883832: TT).[14](#hep41113-bib-0014){ref-type="ref"}, [15](#hep41113-bib-0015){ref-type="ref"} These changes conferred a decrease in the strength of immune responses. The CC genotype of rs12979860 (IFNL4), which is more prevalent in East Asia, is associated with a lower baseline IFNL3 (interleukin‐28B) expression.[16](#hep41113-bib-0016){ref-type="ref"}, [17](#hep41113-bib-0017){ref-type="ref"} The IFNL4 open reading frame is truncated by a polymorphic frame‐shift insertion (rs368234815), which turns IFNL4 into a polymorphic pseudogene in East Asian populations.[18](#hep41113-bib-0018){ref-type="ref"} Because the prevalence of HBsAg is higher in Africa than in Europe or South Asia, these trends of decreased immune protein expression are not related to HBV‐specific immune tolerance. Although it is clear that Europeans and South Asians are two different races, they showed similar genetic adaptions when they migrated out of Africa. These changes suggest that the decreased expression of immune‐related genes might have been an important survival strategy when humans migrated into new territories and faced new pathogens. The contact between different races of humans may induce devastating diseases, for example, when the New World was discovered by Christopher Columbus in 1492.[25](#hep41113-bib-0025){ref-type="ref"} A similar situation was well documented when Japan sent troops to Taiwan in 1874 and 1895; only 0.1% to 0.3% of soldiers died in battle, while around 10% died of diseases in a short period of time after arrival.[26](#hep41113-bib-0026){ref-type="ref"}

Our second principal result is that the allele frequency of HBV‐ and HLA‐related SNPs show marked differences between South and East Asian genome samples (Fig. [2](#hep41113-fig-0002){ref-type="fig"}B). Eight of the 12 SNPs differed significantly between BEB and CDX (Table [2](#hep41113-tbl-0002){ref-type="table-wrap"}; *P \<* 0.001). These two populations are located at the junction of South and East Asia. The unique allele types of HBV‐related SNPs in East Asian populations are different from those of other geographic populations. These genotypic changes could be related to antigen presentation and could be associated with persistent HBV infection.[7](#hep41113-bib-0007){ref-type="ref"}, [8](#hep41113-bib-0008){ref-type="ref"}, [9](#hep41113-bib-0009){ref-type="ref"}, [10](#hep41113-bib-0010){ref-type="ref"}, [11](#hep41113-bib-0011){ref-type="ref"}, [12](#hep41113-bib-0012){ref-type="ref"}, [13](#hep41113-bib-0013){ref-type="ref"} Our findings are in agreement with a higher prevalence of HBsAg in East Asia than in South Asia (Fig. [1](#hep41113-fig-0001){ref-type="fig"}). These genotypic populations are generally overlapped in the Y chromosome haplogroup O1‐O3 distribution map ([https://en.wikipedia.org/wiki/Human_Y‐chromosome_DNA\_ haplogroup](https://en.wikipedia.org/wiki/Human_Y-chromosome_DNA_haplogroup)) as they started in the Indo‐China Peninsula and travelled to northern China and Japan.

Given the results, we theorized on the reason behind the dramatic allele differences in HBV‐related SNPs between BEB in South Asia and CDX in East Asia. One possible explanation for this variation involves the consideration of environmental landscape factors.[27](#hep41113-bib-0027){ref-type="ref"} For example, Bangladesh is a predominately rich, fertile, and flat land, with many areas situated less than 12 m above sea level. On the other hand, Xishuangbanna is situated in a mountainous and forested area that has the largest diversity of plants and animals in China.

Regions with higher plant and animal biodiversity are often accompanied by an increased range and abundance of vector‐borne or nonvector‐borne diseases.[28](#hep41113-bib-0028){ref-type="ref"}, [29](#hep41113-bib-0029){ref-type="ref"}, [30](#hep41113-bib-0030){ref-type="ref"}, [31](#hep41113-bib-0031){ref-type="ref"}, [32](#hep41113-bib-0032){ref-type="ref"}, [33](#hep41113-bib-0033){ref-type="ref"}, [34](#hep41113-bib-0034){ref-type="ref"} Accordingly, the inhabitants of these areas should be able to tolerate an increased number of unfamiliar microorganisms. We speculated that the subjects who demonstrate direct and strong immune responses may die of a cytokine storm in fulminant hepatitis, severe acute respiratory syndrome, influenza, and other infections.[30](#hep41113-bib-0030){ref-type="ref"}, [31](#hep41113-bib-0031){ref-type="ref"}, [32](#hep41113-bib-0032){ref-type="ref"}, [33](#hep41113-bib-0033){ref-type="ref"}, [34](#hep41113-bib-0034){ref-type="ref"} This concept is supported by a lower mortality rate from influenza H1N1 in Asia than in Australia, New Zealand, and North America.[35](#hep41113-bib-0035){ref-type="ref"}

Cytokine storm was first described in graft‐versus‐host disease and was soon also identified in many infectious diseases[36](#hep41113-bib-0036){ref-type="ref"}; many cytokines, chemokines, and complements are involved.[37](#hep41113-bib-0037){ref-type="ref"}, [38](#hep41113-bib-0038){ref-type="ref"}, [39](#hep41113-bib-0039){ref-type="ref"} The immune‐related SNPs selected in this study that included IFN (IFNL4), tumor necrosis factor‐receptor (CD40), and complements (CFB) are all participants in cytokine storms. HLA class II molecules are associated with antigen presentation and are also modulated by cytokines.[40](#hep41113-bib-0040){ref-type="ref"} A cytokine storm is considered to be a hyper‐reaction of the immune response to a pathogen that may cause fulminant disease and mortality.[36](#hep41113-bib-0036){ref-type="ref"}, [37](#hep41113-bib-0037){ref-type="ref"}, [38](#hep41113-bib-0038){ref-type="ref"}, [39](#hep41113-bib-0039){ref-type="ref"} When humans migrate to a new territory, they face many unfamiliar pathogens. Those subjects with a strong immune response will die of disease, but those subjects with a weak immune response to the pathogens may survive. Chronic HBV infection with an immune tolerance stage is an example of a weak immune response.[3](#hep41113-bib-0003){ref-type="ref"}, [4](#hep41113-bib-0004){ref-type="ref"}, [5](#hep41113-bib-0005){ref-type="ref"}

East Asian populations carry similar allele types of HBV‐related SNPs (Fig. [2](#hep41113-fig-0002){ref-type="fig"}B), although the environments of northern China and Japan differ substantially from those of southern China and the Indo‐China Peninsula.[41](#hep41113-bib-0041){ref-type="ref"} We therefore propose that there was a significant physical block to gene flow on the Indo‐China Peninsula. Most of the survivors in East Asia exhibit delayed HBV‐related immune clearance genotypes. This could have been a survival strategy to pass through the Indo‐China Peninsula and southern China during human migration. Such HLA class II genotypes are aimed toward an immune tolerance strategy.[7](#hep41113-bib-0007){ref-type="ref"}, [8](#hep41113-bib-0008){ref-type="ref"}, [9](#hep41113-bib-0009){ref-type="ref"}, [10](#hep41113-bib-0010){ref-type="ref"}, [11](#hep41113-bib-0011){ref-type="ref"}, [12](#hep41113-bib-0012){ref-type="ref"}, [13](#hep41113-bib-0013){ref-type="ref"} These changes were successful because this group of people spread to northern China and Japan and have become the largest population in the world numerically. However, such a survival benefit may have been a trade‐off with cold tolerance as these populations were unable to cross the Bering Strait in large numbers. Indigenous Americans do not show the same HBV‐related allele pattern; they have a low prevalence of chronic HBV infection and high influenza‐related mortality rates.[1](#hep41113-bib-0001){ref-type="ref"}, [2](#hep41113-bib-0002){ref-type="ref"}, [35](#hep41113-bib-0035){ref-type="ref"}

Overall, we identified two genetic adaptations that occurred during human migration. The first was the decreased expression of immune‐related genes after leaving Africa; the second was the evolution of an HLA system with migration into the Indo‐China Peninsula. Both events may have aimed to decrease the strength of the immune response and avoid cytokine storms when facing different types of pathogens. The high prevalence of chronic HBV infection in East Asia could be a consequence of such a strategy. However, persistent HBV infection‐related HLA genotypes are not present in the African population (Fig. [2](#hep41113-fig-0002){ref-type="fig"}B) and cannot be responsible for the high prevalence of HBsAg in Africa.

Different genetic and nongenetic mechanisms of chronic HBV infection are presented between East Asian and African populations.[4](#hep41113-bib-0004){ref-type="ref"}, [42](#hep41113-bib-0042){ref-type="ref"}, [43](#hep41113-bib-0043){ref-type="ref"}, [44](#hep41113-bib-0044){ref-type="ref"} We summarize the differences on HBsAg carriers between East Asia and Africa in Table [3](#hep41113-tbl-0003){ref-type="table-wrap"}. These differences may provide a clue for the mechanism of the function of SNPs in the persistent HBV infection. The high prevalence of low‐expression‐type immune‐related SNPs and chronic HBV infection‐related SNPs on the HLA locus may be a reason for a longer hepatitis B e antigen (HBeAg)‐positive phase in East Asia. IFN‐alpha has been recommended for treatment of HBeAg‐positive chronic hepatitis B. In a larger series from pediatric patients, IFN‐alpha was found to be an effective therapy in chronic hepatitis B with severe inflammation that facilitates HBeAg seroconversion in earlier life.[45](#hep41113-bib-0045){ref-type="ref"} In addition, HBV‐ and HLA‐related SNPs are also associated with spontaneous HBeAg seroconversion.[46](#hep41113-bib-0046){ref-type="ref"}, [47](#hep41113-bib-0047){ref-type="ref"}, [48](#hep41113-bib-0048){ref-type="ref"} These genetic polymorphisms could be a reason for an early HBeAg seroconversion and a lower vertical transmission in Africa compared to East Asia.

###### 

DIFFERENCES IN CHRONIC HBV INFECTION BETWEEN AFRICA AND EAST ASIA

                               Africa            East Asia
  ---------------------------- ----------------- ----------------
  HBsAg prevalence             High              High
  Host gene pattern                              
  HBV‐ and HLA‐ related SNPs   Rare              Common
  Immune‐related SNPs          High expression   Low expression
  HBV genotype                 A,D,E             B,C
  Vertical transmission        Low               High
  Early HBeAg seroconversion   Common            Low

It is well known that HBV genotypes A, B, and D show an earlier HBeAg seroconversion compared to genotype C.[42](#hep41113-bib-0042){ref-type="ref"}, [44](#hep41113-bib-0044){ref-type="ref"} This early HBeAg seroconversion was suggested to be the reason of low vertical transmission in Africa.[49](#hep41113-bib-0049){ref-type="ref"} However, HBV genotype B also had an early HBeAg seroconversion but had a high vertical transmission rate in East Asia.[4](#hep41113-bib-0004){ref-type="ref"} Therefore, host factors rather than HBV genotypes alone should be considered for the high vertical transmission rate in East Asia. Most HBV‐related genome‐wide association studies were done in East Asia. We need studies to understand the genetic roles in persistent HBV infection in African populations.

Our study found two stages of genetic changes toward a weak immune response when humans migrated out of Africa. These changes could be a survival strategy for avoiding cytokine storms and surviving in new environments.
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